Progress in cytomegalovirus vaccine development

Herpes

Volumn 12, Issue 3, 2005, Pages 66-75

  Schleiss, Mark ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Congenital cytomegalovirus infection; Cytomegalovirus; Cytomegalovirus glycoprotein B; Cytomegalovirus vaccines; Herpesvirus vaccines; Torch infections

Indexed keywords

ANTIVIRUS AGENT; CYTOMEGALOVIRUS VACCINE; DNA VACCINE; GANCICLOVIR; GLYCOPROTEIN H; GLYCOPROTEIN L; GLYCOPROTEIN M; GLYCOPROTEIN N; GLYCOPROTEIN O; GLYCOPROTEIN UL18; GLYCOPROTEIN US2; GLYCOPROTEIN US3; GLYCOPROTEIN US6; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; LIVE VACCINE; MONOCLONAL ANTIBODY; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PEPTIDE; PHOSPHOPROTEIN 150; PHOSPHOPROTEIN 28; PHOSPHOPROTEIN 50; PHOSPHOPROTEIN 52; PHOSPHOPROTEIN 65; PHOSPHOPROTEIN 71; PROTEIN IE1; RECOMBINANT GLYCOPROTEIN B; UNCLASSIFIED DRUG; VIRUS VECTOR;

CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONGENITAL INFECTION; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DENSE BODY; DISEASE COURSE; DRUG INDUCED HEADACHE; FATIGUE; FEVER; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INFECTION RISK; INJECTION SITE REACTION; MORBIDITY; MYALGIA; NONHUMAN; PASSIVE IMMUNIZATION; POPULATION; PREGNANCY; PRIORITY JOURNAL; PROTECTION; REVIEW; VACCINATION; VIRUS STRAIN; VIRUS TRANSMISSION;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; DRUG DESIGN; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RESEARCH;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HERPESVIRIDAE;

EID: 29544450845     PISSN: 09697667     EISSN: 14701537     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Marshall GS. Cytomegalovirus vaccines - two decades of progress. Herpes 1997;4:20-24.
2. Weller TH. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I. N Engl J Med 1971;285:203-214.
3. Weller TH. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. II. N Engl J Med 1971;285:267-274.
4. Pomeroy C, Englund JA. Cytomegalovirus: epidemiology and infection control. Am J Infect Control 1987;15:107-119.
5. Strangert K, Carlstrom G, Jeansson S, Nord CE. Infections in preschool children in group day care. Acta Paediatr Scand 1976;65:455-463.
6. Strom J. A study of infections and illnesses in a day nursery based on inclusion-bearing cells in the urine and infectious agent in faeces, urine and nasal secretion. Scand J Infect Dis 1979; 11:265-269.
7. Pass RF, Hutto SC, Reynolds DW, Polhill RB. Increased frequency of cytomegalovirus infection in children in group day care. Pediatrics 1984;74:121-126.
8. Adler SP. The molecular epidemiology of cytomegalovirus transmission among children attending a day care center. J Infect Dis 1985; 152:760-768.
9. Pass RF, Hutto C, Ricks R, Cloud GA. Increased rate of cytomegalovirus infection among parents of children attending day-care centers. N Engl J Med 1986;314: 1414-1418.
10. Zanghellini F, Boppana SB, Emery VC, Griffiths PD, Pass RF. Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 1999;180:702-707.
11. Stanberry LR, Rosenthal SL, Mills L, Succop PA, Biro FM, Morrow RA et al. Longitudinal risk of herpes simplex virus (HSV) type 1, HSV type 2, and cytomegalovirus infections among young adolescent girls. Clin Infect Dis 2004; 39:1433-1438.
12. Cohen JI, Corey GR. Cytomegalovirus infection in the normal host. Medicine 1985;64:100-114.
13. Arav-Boger R, Pass RF. Diagnosis and management of cytomegalovirus infection in the newborn. Pediatr Ann 2002;31:719-725.
14. Pass RF. Cytomegalovirus infection. Pediatr Rev 2002;23:163-170.
15. Griffiths PD. Strategies to prevent CMV infection in the neonate. Semin Neonatol 2002;7:293-299.
16. Schleiss MR. Vertically transmitted herpesvirus infections. Herpes 2003; 10:4-11.
17. Whitley RJ. Congenital cytomegalovirus infection: epidemiology and treatment. Adv Exp Med Biol 2004; 549:155-160.
18. Demmler GJ. Congenital cytomegalovirus infection and disease. Adv Pediatr Infect Dis 1996;11:135-162.
19. Bale JF, Miner L, Petheram SJ. Congenital cytomegalovirus infection. Curr Treat Options Neurol 2002;4: 225-230.
20. Pass RF, Stagno S, Myers GJ, Alford CA. Outcome of symptomatic congenital cytomegalovirus infection: results of long-term longitudinal follow-up. Pediatrics 1980;66:758-762.
21. Noyola DE, Demmler GJ, Nelson CT, Griesser C, Williamson WD, Atkins JT. Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection. J Pediatr 2001; 138:325-331.
22. Dahle AJ, Fowler KB, Wright JD, Boppana SB, Britt WJ, Pass RF. Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. J Am Acad Audiol 2000; 11:283-290.
23. Strauss M. Human cytomegalovirus labyrinthitis. Am J Otolaryngol 1990;11: 292-298.
24. Pass RF. Immunization strategy for prevention of congenital cytomegalovirus infection. Infect Agents Dis 1996;5:240-244.
25. Porath A, McNutt RA, Smiley LM, Weigle KA. Effectiveness and cost benefit of a proposed live cytomegalovirus vaccine in the prevention of congenital disease. Rev Infect Dis 1990;12:31-40.
26. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R; National Vaccine Advisory Committee. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 2004;39:233-239.
27. Stratton KR, Durch JS and Lawrence RS (eds). Vaccines for the 21st Century: A Tool for Decision-making, Washington DC: Institute of Medicine, 1999.
28. Kimberlin DW, Lin CY, Sanchez PJ, Demmler GJ, Dankner W, Shelton M et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003;143:16-25.
29. Schleiss MR, McVoy MA. Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy. Expert Rev Anti Infect Ther 2004;2:389-403.
30. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992;326: 663-667.
31. Adler SP, Starr SE, Plotkin SA, Hempfling SH, Buis J, Manning ML et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995;171:26-32.
32. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 2001;344: 1366-1371.
33. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003;289:1008-1011.
34. Fowler KB, Stagno S, Pass RF. Interval between births and risk of congenital cytomegalovirus infection. Clin Infect Dis 2004;38: 1035-1037.
35. Lazzarotto T, Spezzacatena P, Varani S, Gabrielli L, Pradelli P, Guerra B et al. Anticytomegalovirus (anti-CMV) immunoglobulin G avidity in identification of pregnant women at risk of transmitting congenital CMV infection. Clin Diagn Lab Immunol 1999;6:127-129.
36. Griffiths PD, McLean A, Emery VC. Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine 2001;19:1356-1362.
37. Melnick JL, Adam E, DeBakey ME. Cytomegalovirus and atherosclerosis. Bioessays 1995;17:899-903.
38. Trzonkowski P, Mysliwska J, Szmit E, Wieckiewicz J, Lukaszuk K, Brydak LB et al. Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination-an impact of immunosenescence. Vaccine 2003;21:3826-3836.
39. Pawelec G, Akbar A, Caruso C, Solana R, Grubeck-Loebenstein B, Wikby A. Human immunosenescence: is it infectious? Immunol Rev 2005;205:257-268.
40. Pereyra F, Rubin RH. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 2004;17:357-361.
41. Boeckh M, Fries B, Nichols WG. Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation. Pediatr Transplant 2004;8(Suppl 5): 19-27.
42. Bueno J, Ramil C, Green M. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients. Paediatr Drugs 2002;4:279-290.
43. Blackman SC, Lurain NS, Witte DP, Filipovich AH, Groen P, Schleiss MR. Emergence and compartmentalization of fatal multi-drug-resistant cytomegalovirus infection in a patient with autosomal-recessive severe combined immune deficiency. J Pediatr Hematol Oncol 2004;26:601-605.
44. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004;103:2003-2008.
45. Griffiths PD. The indirect effects of virus infections. Rev Med Virol 2003;13:1-3.
46. Elek SD, Stern H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1974;i:1-5.
47. Neff BJ, Weibel RE, Buynak EB, McLean AA, Hilleman MR. Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169. Proc Soc Exp Biol Med 1979;160:32-37.
48. Stern H. Live cytomegalovirus vaccination of healthy volunteers: eight-year follow-up studies. Birth Defects Orig Artic Ser 1984; 20:263-269.
49. Just M, Buergin-Wolff A, Emoedi G, Hernandez R. Immunisation trials with live attenuated cytomegalovirus TOWNE 125. Infection 1975;3:111-114.
50. Gonczol E, Ianacone J, Furlini G, Ho W, Plotkin SA. Humoral immune response to cytomegalovirus Towne vaccine strain and to Toledo low-passage strain. J Infect Dis 1989;159:851-859.
51. Adler SP, Hempfling SH, Starr SE, Plotkin SA, Riddell S. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J 1998;17: 200-206.
52. Gehrz RC, Christianson WR, Linner KM, Groth KE, Balfour HH, Jr. Cytomegalovirus vaccine. Specific humoral and cellular immune responses in human volunteers. Arch Intern Med 1980;140: 936-939.
53. Starr SE, Glazer JP, Friedman HM, Farquhar JD, Plotkin SA. Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine. J Infect Dis 1981;143:585-589.
54. Fleisher GR, Starr SE, Friedman HM, Plotkin SA. Vaccination of pediatric nurses with live attenuated cytomegalovirus. Am J Dis Child 1982;136:294-296.
55. Plotkin SA, Starr SE, Friedman HM, Gonczol E, Weibel RE. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis 1989;159: 860-865.
56. Quinnan GV, Jr, Delery M, Rook AH, Frederick WR, Epstein JS, Manischewitz JF et al. Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. Ann Intern Med 1984;101:478-483.
57. Glazer JP, Friedman HM, Grossman RA, Starr SE, Barker CF, Perloff LJ et al. Live cytomegalovirus vaccination of renal transplant candidates. A preliminary trial. Ann Intern Med 1979;91:676-683.
58. Marker SC, Simmons RL, Balfour HH, Jr. Cytomegalovirus vaccine in renal allograft recipients. Transplant Proc 1981;13: 117-119.
59. Plotkin SA, Smiley ML, Friedman HM, Starr SE, Fleisher GR, Wlodaver C et al. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet 1984;i:528-530.
60. Brayman KL, Dafoe DC, Smythe WR, Barker CF, Perloff LJ, Naji A et al. Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine. Interim results of a randomized controlled trial. Arch Surg 1988;123: 1502-1508.
61. Plotkin SA, Starr SE, Friedman HM, Brayman K, Harris S, Jackson S et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med 1991;114:525-531.
62. Plotkin SA, Higgins R, Kurtz JB, Morris PJ, Campbell DA, Jr, Shope TC et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994;58: 1176-1178.
63. Balfour HH, Jr, Sachs GW, Welo P, Gehrz RC, Simmons R. Cytomegalovirus vaccine in renal transplant candidates: progress report of a randomized, placebo-controlled, double-blind trial. Birth Defects 1984;20: 289-304.
64. Balfour HH, Jr. Prevention of cytomegalovirus disease in renal allograft recipients. Scand J Infect Dis 1991;80 (Suppl):88-93.
65. Sachs GW, Simmons RL, Balfour HH, Jr. Cytomegalovirus vaccine: persistence of humoral immunity following immunization of renal transplant candidates. Vaccine 1984;2:215-218.
66. Schleiss MR, Heineman TC. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 2005;4: 381-406.
67. Huang ES, Huong SM, Tegtmeier GE, Alford C. Cytomegalovirus: genetic variation of viral genomes. Ann N Y Acad Sci 1980; 354:332-346.
68. Mocarski ES, Liu AC, Spaete RR. Structure and variability of the sequence in the genome of human cytomegalovirus (Towne strain). J Gen Virol 1987;68: 2223-2230.
69. Prichard MN, Penfold ME, Duke GM, Spaete RR, Kemble GW. A review of genetic differences between limited and extensively passaged human cytomegalovirus strains. Rev Med Virol 2001;11:191-200.
70. Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, Spaete RR. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 1996;70:78-83.
71. Murphy E, Yu D, Grimwood J, Schmutz J, Dickson M, Jarvis MA et al. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc Natl Acad Sci U S A 2003;100:14976-14981.
72. Wang D, Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 2005;79:10330-10338.
73. Gerna G, Percivalle E, Lilleri D, Lozza L, Fornara C, Hahn G et al. Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol 2005;86: 275-284.
74. Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, Sarasini A et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 2004;78: 10023-10033.
75. Kemble G, Duke G, Winter R, Spaete R. Defined large-scale alterations of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids. J Virol 1996;70:2044-2048.
76. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005;202: 673-685.
77. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 1990;64:1079-1085.
78. Spaete RR, Thayer RM, Probert WS, Masiarz FR, Chamberlain SH, Rasmussen L et al. Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology 1988;167: 207-225.
79. Spaete RR. A recombinant subunit vaccine approach to HCMV vaccine development. Transplant Proc 1991;23 (Suppl 3):90-96.
80. Spaete RR, Saxena A, Scott PI, Song GJ, Probert WS, Britt WJ et al. Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne. J Virol 1990; 64:2922-2931.
81. Pass RF, Duliege AM, Boppana S, Sekulovich R, Percell S, Britt W et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999; 180:970-975.
82. Frey SE, Harrison C, Pass RF, Yang E, Boken D, Sekulovich RE et al. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis 1999;180:1700-1703.
83. Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J 2002;21: 133-138.
84. Zhang C, Pass RF. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine. Vaccine 2004;23:507-510.
85. Griffiths PD. Available at: http://crisp.cit.nih.gov/crisp/CRISP_LIB. getdoc?textkey= 6947730&p_grant_num= 5R01AI051355-03&p_query= &ticket=17786596&p_audit_ session_id=82568303&p_ keywords=. Last accessed 28 September 2005.
86. Wells DE, Vugler LG, Britt WJ. Structural and immunological characterization of human cytomegalovirus gp55-116 (gB) expressed in insect cells. J Gen Virol 1990;71:873-880.
87. Tackaberry ES, Dudani AK, Prior F, Tocchi M, Sardana R, Altosaar I et al. Development of biopharmaceuticals in plant expression systems: cloning, expression and immunological reactivity of human cytomegalovirus glycoprotein B (UL55) in seeds of transgenic tobacco. Vaccine 1999;17:3020-3029.
88. Kari B, Gehrz R. Analysis of human antibody responses to human cytomegalovirus envelope glycoproteins found in two families of disulfide linked glycoprotein complexes designated gC-I and gC-II. Arch Virol 1990;114:213-228.
89. Mach M, Kropff B, Dal Monte P, Britt W. Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73). J Virol 2000;74:11881-11892.
90. Mach M, Kropff B, Kryzaniak M, Britt W. Complex formation by glycoproteins M and N of human cytomegalovirus: structural and functional aspects. J Virol 2005;79:2160-2170.
91. Urban M, Klein M, Britt WJ, Hassfurther E, Mach M. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 1996;77: 1537-1547.
92. Simpson JA, Chow JC, Baker J, Avdalovic N, Yuan S, Au D et al. Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites. J Virol 1993;67:489-496.
93. Varnum SM, Streblow DN, Monroe ME, Smith P, Auberry KJ, Pasa-Tolic L et al. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol 2004;78:10960-10966.
94. Skinner MA, Laidlaw SM, Eldaghayes I, Kaiser P, Cottingham MG. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev Vaccines 2005;4:63-76.
95. Gonczol E, Berensci K, Pincus S, Endresz V, Meric C, Paoletti E et al. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 1995;13:1080-1085.
96. Adler SP, Plotkin SA, Gonczol E, Cadoz M, Meric C, Wang JB et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 1999;180:843-846.
97. Bernstein DI, Schleiss MR, Berencsi K, Gonczol E, Dickey M, Khoury P et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J Infect Dis 2002;185:686-690.
98. Wang Z, La Rosa C, Maas R, Ly H, Brewer J, Mekhoubad S et al. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J Virol 2004;78:3965-3976.
99. Berencsi K, Gyulai Z, Gonczol E, Pincus S, Cox WI, Michelson S et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 2001;183:1171-1179.
100. Wang Z, La Rosa C, Mekhoubad S, Lacey SF, Villacres MC, Markel S et al. Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood 2004;104: 847-856.
101. Lundstrom K. Alphavirus vectors for vaccine production and gene therapy. Expert Rev Vaccines 2003;2:447-459.
102. http://www.alphavax.com/products/cmv.aspx. Last accessed 9 November 2005.
103. Temperton NJ. DNA vaccines against cytomegalovirus: current progress. Int J Antimicrob Agents 2002;19:169-172.
104. Endresz V, Kari L, Berencsi K, Kari C, Gyulai Z, Jeney C et al. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization. Vaccine 1999;17:50-58.
105. Endresz V, Burian K, Berencsi K, Gyulai Z, Kari L, Horton H et al. Optimization of DNA immunization against human cytomegalovirus. Vaccine 2001;19:3972-3980.
106. Temperton NJ, Quenelle DC, Lawson KM, Zuckerman JN, Kern ER, Griffiths PD et al. Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides. J Med Virol 2003;70:86-90.
107. Evans TG, Wloch M, Hermanson G, Selinsky C, Geall A, Kaslow D. Phase 1 trial of a bivalent, formulated plasmid DNA CMV vaccine for use in the transplant population (abstract). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC, 2004.
108. Paston SJ, Dodi IA, Madrigal JA. Progress made towards the development of a CMV peptide vaccine. Hum Immunol 2004;65:544-549.
109. Ben Mohamed L, Krishnan R, Longmate J, Auge C, Low L, Primus J et al. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response. Hum Immunol 2000;61: 764-779.
110. Zaia JA, Gallez-Hawkins G, Li X, Yao ZQ, Lomeli N, Molinder K et al. Infrequent occurrence of natural mutations in the pp65(495-503) epitope sequence presented by the HLA A*0201 allele among human cytomegalovirus isolates. J Virol 2001;75:2472-2474.
111. Irmiere A, Gibson W. Isolation and characterization of a noninfectious virion-like particle released from cells infected with human strains of cytomegalovirus. Virology 1983;130:118-133.
112. Gibson W, Irmiere A. Selection of particles and proteins for use as human cytomegalovirus subunit vaccines. Birth Defects 1984;20:305-324.
113. Pepperl S, Munster J, Mach M, Harris JR, Plachter B. Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J Virol 2000;74: 6132-6146.
114. Pepperl-Klindworth S, Frankenberg N, Riegler S, Plachter B. Protein delivery by subviral particles of human cytomegalovirus. Gene Ther 2003;10:278-284.
115. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-1044.
116. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2001;202:379-386.
117. Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RL et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987;317: 1049-1054.
118. Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, Tierney DK et al. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001;7:343-351.
119. Nigro G, Adler SP, La Torre R, Best AM. Passive maternal immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005;353: 1350-1362.